Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Open Access

: Emerging Frontiers in the Treatment of Non-small Cell Lung Cancer: Innovations and Clinical Advances

View Full Paper
Ask AI
Bookmark
Share

Authors

YAYang AnCZChanghao ZuXZXiaotong Zhuang

Discussion

Loading...

Member takes

Overview

Review highlights evolving chemotherapy roles and integration of immunotherapies in non-small cell lung cancer, suggesting new strategies for precision oncology.

Key Points

  • Chemotherapy remains essential in the dynamic treatment of non-small cell lung cancer, especially for patients without actionable mutations.
  • Recent advancements have improved patient outcomes through targeted agents and immunotherapies, highlighting the significance of treatment sequencing.
  • The review emphasizes the integration of novel therapies, like immune checkpoint inhibitors, into existing chemotherapy regimens for enhanced efficacy.
  • Emerging strategies such as antibody-drug conjugates and molecular personalization via circulating tumor DNA are shaping the future of precision oncology.

Cite This Study

An et al. (2025) studied this question.

synapsesocial.com/papers/68c243f6b210217d647a910dhttps://doi.org/10.69854/jcq.2025.0024
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic Progress in Non-Small Cell Lung Cancer (NSCLC): Molecular Targets and Immunotherapy2025 · 1 citations
  2. 2Comprehensive Advances in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Precision Therapy2025
  3. 3Advances in Multimodality Management of Localized NSCLC2025
  4. 4Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017–20252025
  5. 5Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC)2025